Correction: Mol Cancer 20, 68 (2021)
https://doi.org/10.1186/s12943-021-01359-x
Following the publication of the original paper [1], we have found several inadvertent errors in the figures recently. Those errors are as following:
The images for transwell assays in Fig. 1G (invasion assay for “IGF2BP1 group” and “sgCtrl group”), Fig. 3A (invasion assay for “vector group”), Fig. 3C (migration assay for “vector/IGF2BP1 group”, “circPTPRA/empty group”, and “circPTPRA/IGF2BP1 group”; invasion assay for “vector/empty group”, “vector/IGF2BP1 group”, “circPTPRA/empty group”, and “circPTPRA/IGF2BP1 group”), Fig. 5A (migration assay for “vector/empty group”, “circPTPRA/empty group”, “vector/MYC group”, and “circPTPRA/MYC group”), and Fig. S1F (migration assay for “IGF2BP1 group”; invasion assay for “empty group”, “sgCtrl group”, and “sgIGF2BP1 group”) were misused. After checking the original data, we found that these errors happened inadvertently during the stage of saving the images, partially due to two projects were conducted simultaneously. Besides, the image for lung metastatic colonization in Fig. 1I (“sgIGF2BP1#1 group” No.1) was misused, and the MYC and FSCN1 mRNA half-life in Fig. 6B were mistakenly displayed. The XY axis labels in Fig. S1E were misplaced. The corrected version of Fig. 1G&I, Fig. 3A&C, Fig. 5A, Fig. 6B and Fig. S1E&F have been provided. Besides, we made a mistake to describe “male nude mice” as “female nude mice” in the Methods. Since these errors do not originate from original experiments, there is no effect on the interpretation or conclusion of this work. We sincerely apologize to the editor, reviewers and readers for the errors and any confusion it may have caused.
Reference
Xie F, Huang C, Liu F, et al. CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression. Mol Cancer. 2021;20:68. https://doi.org/10.1186/s12943-021-01359-x.
Author information
Authors and Affiliations
Corresponding authors
Supplementary Information
Additional file 1: Figure S1.
A. and B. The efficiencies of stable models of IGF2BP1 overexpression or knockout in EJ and T24T cell lines. C. Sanger sequencing of genomic DNAs to validate IGF2BP1 knockout in EJ and T24T cells. The mutation patterns on the two alleles are highlighted in red. The red arrow represents the cleavage site. D. CCK-8 assay was performed to evaluate cell viability in BC cells with stable overexpression or knockout of IGF2BP1. E. and F. Cell cycle analysis and representative images and quantification of transwell assay indicating the proliferation and invasion of EJ cells with stable overexpression or knockout of IGF2BP1. The data are the means ± SEM of three independent experiments. **, P < 0.01.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Xie, F., Huang, C., Liu, F. et al. Correction: CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression. Mol Cancer 21, 205 (2022). https://doi.org/10.1186/s12943-022-01677-8
Published:
DOI: https://doi.org/10.1186/s12943-022-01677-8